Abstract:Since the approval of the first checkpoint inhibitor, ipilimumab (α-CTLA4), there continues to be enthusiasm around leveraging the immune system to eradicate solid tumors. However, unknowns about the cellular mechanism(s) that cause some patients to durably respond while others relapse, continue to stymie the field. To support ongoing efforts elucidating cell subsets responsible for differences in patient responses, we aim to evaluate the functional heterogeneity of T-cell subsets responding to checkpoint inhibitors in mouse models of solid tumors. Single-cell RNA-seq has enabled discoveries of transcriptionally defined cell subsets, but understanding their function require inference from transcription, flow-based validation biased by pre-selection of subsets with specific markers, or reliance on surrogate markers for cell-extrinsic functions (e.g., cytotoxicity). Thus, functional heterogeneity could be obscured. To address this, we leveraged a novel technology that converges live, cellular functions with transcriptomics at the resolution of single cell-cell interactions. This technology captures tens of thousands of individual cells or defined combinations of groups of cells in bio-compatible hydrogel compartments, enabling longitudinal imaging over days to weeks. Throughout this period, functions are characterized via bright-field or immunofluorescence readouts, including antibodies, cytokine capture beads, and dyes. Cells are then lysed within compartments to generate barcoded libraries for mRNA-sequencing and gene signatures from individual cells computationally deconvoluted. With this technology, we developed a novel assay that enables longitudinal, unbiased functional characterization of individual T cells mapped to single-cell transcriptomics. Single mouse primary T cells were encapsulated with one or more MC38 target cells and imaged over time. We validated combinations of different readouts can be measured from the same T-cell, including cell-counts for proliferation, CD8/3 expression to differentiate T cells from target cells, activation markers, and / or target cell death via Sytox. Thus, single T cells can be multi-functionally evaluated over time, enabling the study of attributes inaccessible at high scale with prior technologies, including kinetics of killing or the number of target cells killed by a single T-cell. For assays combining cytotoxicity and surface receptors, we generated barcoded libraries from functionally characterized T cells for sequencing and developed an analytical pipeline that deconvolutes mRNA from single T cells mapped to their multi-functional profiles, to identify novel pathways that regulate anti-tumor functions. We will leverage this workflow to functionally characterize single T cells in tumor-bearing mice treated with checkpoint inhibitors and map the data to underlying transcriptomics. In doing so, we aim to discover functional subsets, potentially with identical transcriptional profiles, to support hypothesis generation around mechanisms governing anti-tumor efficacy of checkpoint inhibitors. Citation Format: Jacqueline Yee, Praveer Sharma, Yunmin Li, Isaac Thomas, Pier F Gherardini, Teresa Ai, Mostafa Ronaghi, Gary Schroth, Matthew H Spitzer. Novel workflow for characterizing T-cell functional heterogeneity in response to checkpoint inhibitors [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr A025.

Assessing clonal changes in T cells over time following immunotherapy is a breeze with Cyclone

Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells

Single-cell meta-analysis of T cells reveals clonal dynamics of response to checkpoint immunotherapy

TIL the end: Tracking T cell clonotype dynamics during adoptive cell therapy

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion.

Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma

Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment

Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies

Cellular Dynamics Upon Immune Checkpoint Inhibition

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

Abstract 6397: Immune profiling for improving responsiveness to ipilimumab plus nivolumab checkpoint blockade treatment in patients with metastatic melanoma

T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors

Single-Cell Transcriptomic Analysis Reveals the Crosstalk Propensity Between the Tumor Intermediate State and the CD8+ T Exhausted State to be Associated with Clinical Benefits in Melanoma

Abstract 3247: Dynamic Clonality of T Cell Receptor Differentiate Atypical Progression in NSCLC Patients Treated with PD-1/PD-L1inhibitors

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

Clonal tracing reveals diverse patterns of response to immune checkpoint blockade

Abstract A025: Novel workflow for characterizing T-cell functional heterogeneity in response to checkpoint inhibitors

The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment

Combinatorial immunotherapy induces tumor-infiltrating CD8+ T cells with distinct functional, migratory, and stem-like properties

A T cell repertoire timestamp is at the core of responsiveness to CTLA-4 blockade